Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sana Biotechnology, Inc. - Common Stock (NQ:SANA)

1.435 -0.195 (-11.96%)
Streaming Delayed Price Updated: 10:55 AM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sana Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Sana Biotechnology Announces the Acceptance of Six Abstracts for Presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
From Sana Biotechnology, Inc
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2023
Via Benzinga
Sana Biotechnology to Host Research & Development Day
From Sana Biotechnology, Inc
Via GlobeNewswire
Morgan Stanley Maintains Overweight Rating for Sana Biotechnology: Here's What You Need To Know
Via Benzinga
Sana Biotechnology Outlines Pipeline Prioritization, Reduces Workforce
Via Benzinga
The Top 3 Biotech Stocks to Watch in 2023
Investors would be wise to keep an eye on the biotech boom, and these top biotech stocks to watch as we get deeper into 2023. 
Via InvestorPlace
Sana Biotechnology Highlights Preclinical Hypoimmune Data for its Allogeneic CAR T Platform and Advancements with its In Vivo Fusogen Platform with Four Presentations at the 2023 AACR Annual Meeting
From Sana Biotechnology, Inc
Via GlobeNewswire
2 Growth Stocks That Jumped 42% and 58% Last Week: Can They Still Climb Higher?
Good news drove shares of these stocks through the roof last week, but investors should be more concerned about their paths forward. 
Via The Motley Fool
Why Shares of Sana Biotechnology Jumped This Week
The company announced details of research on two of its pre-clinical therapies. 
Via The Motley Fool
Why Sana Biotechnology Shares Are Trading Higher Today
Sana Biotechnology (NASDAQ: SANA) shares are trading higher after the company announced the publication of a paper in Nature Communications on hypoimmune-modified allogeneic CD19-directed CAR T cells. 
Via Benzinga
Why ViewRay Shares Are Trading Lower By 32%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers CXApp Inc. (NASDAQ: CXAI) jumped 105% to $3.28 after climbing over 20% on Wednesday. 
Via Benzinga
Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Sana Biotechnology Announces Preclinical Data Published in Nature Communications Demonstrating the Ability of its Hypoimmune Allogeneic CD19-directed CAR T Cells to Evade Immune Rejection and Produce Durable Anti-Tumor Responses
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Announces Preclinical Data Published in Science Translational Medicine Showing its Hypoimmune Pancreatic Islet Cells Evaded Allogeneic and Autoimmune Rejection and Controlled Type 1 Diabetes in Preclinical Model
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Announces the Appointment of Two Pioneers in Drug Discovery and Development to Lead its R&D Organization
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Announces the Acceptance of Four Abstracts for Presentation at the 2023 American Association for Cancer Research Annual Meeting
Late-breaking poster presentation to highlight preclinical data demonstrating that the increased potency of CD8-targeted fusosomes enhances CAR gene delivery to resting primary T cells 
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology to Present at the Cowen 43rd Annual Health Care Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology to Present at the Guggenheim Healthcare Talks 5th Annual Oncology Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 258 companies hit new 52-week lows. 
Via Benzinga
Sana Biotechnology Highlights Hypoimmune Allogeneic CAR T Cell Programs and in vivo Technology Platform with Six Presentations at 2022 ASH Annual Meeting
From Sana Biotechnology, Inc
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
  On Monday, 297 companies reached new 52-week lows. 
Via Benzinga
Sana Biotechnology Confirms Key Program Timelines and Announces Portfolio Prioritization
From Sana Biotechnology, Inc
Via GlobeNewswire
Vodafone, Getty Images Holdings, Haynes International And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Nasdaq gaining more than 200 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Sana Biotechnology Tops BioSpace’s 2023 Best Places to Work Ranking in Small Employer Category
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Announces Several Preclinical Data Presentations at the 64th American Society of Hematology Annual Meeting
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Reports Third Quarter 2022 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
7 Unknown Biotech Stocks That Could Rocket in 2023
Unknown biotech stocks that are poised for a big rally in 2023. Emerging biotech companies with a promising clinical pipeline. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.